ANTI INFECTIVE DRUG SUBSTANCE MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST

  2024-11-27 |   Pages: 200+ |   Report ID: MD-R-2024-11-27-176587 |   Chemical and Material

Historical data: 2018 - 2023

Forecast period: 2024 - 2031

Quantitative units: Revenue in USD million and CAGR from 2024 to 2031

Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Anti infective drug substance Market

Image

1.1 SCOPE OF THE REPORT

1.2 MARKET SEGMENT ANALYSIS

1.3 REGULATORY SCENARIO BY REGION/COUNTRY

1.4 MARKET INVESTMENT SCENARIO STRATEGIC

1.5 MARKET ANALYSIS BY TYPE (USD MILLION)

1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)

2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS

  2.1.1 MARKET DRIVER ANALYSIS

  2.1.2 MARKET RESTRAINT ANALYSIS

  2.1.3 MARKET OPPORTUNITY

  2.1.4 MARKET CHALLENGES

3.1 INDUSTRY TRENDS

  3.1.1 SWOT ANALYSIS

  3.1.2 PESTEL ANALYSIS

  3.1.3 PORTER’S FIVE FORCES ANALYSIS

3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS

4.1 COVID-19 ANALYSIS

5.1 GLOBAL ANTI INFECTIVE DRUG SUBSTANCE MARKET, SALES AREA, TYPE

5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL ANTI INFECTIVE DRUG SUBSTANCE MARKET

7.1 GLOBAL ANTI INFECTIVE DRUG SUBSTANCE MARKET SIZE AND SHARE (2018-2031) (USD MILLION)

8.1 GLOBAL ANTI INFECTIVE DRUG SUBSTANCE MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

8.2 GLOBAL ANTI INFECTIVE DRUG SUBSTANCE MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

9.1 GLOBAL ANTI INFECTIVE DRUG SUBSTANCE MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

9.2 GLOBAL ANTI INFECTIVE DRUG SUBSTANCE MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

10.1 GLOBAL ANTI INFECTIVE DRUG SUBSTANCE MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)

10.2 GLOBAL ANTI INFECTIVE DRUG SUBSTANCE MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)

11.1 NORTH AMERICA ANTI INFECTIVE DRUG SUBSTANCE MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

11.2 NORTH AMERICA ANTI INFECTIVE DRUG SUBSTANCE MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

11.3 NORTH AMERICA ANTI INFECTIVE DRUG SUBSTANCE MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

11.4 NORTH AMERICA ANTI INFECTIVE DRUG SUBSTANCE MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

11.5 NORTH AMERICA ANTI INFECTIVE DRUG SUBSTANCE MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

11.6 NORTH AMERICA ANTI INFECTIVE DRUG SUBSTANCE MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

12.1 EUROPE ANTI INFECTIVE DRUG SUBSTANCE MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

12.2 EUROPE ANTI INFECTIVE DRUG SUBSTANCE MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

12.3 EUROPE ANTI INFECTIVE DRUG SUBSTANCE MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

12.4 EUROPE ANTI INFECTIVE DRUG SUBSTANCE MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

12.5 EUROPE ANTI INFECTIVE DRUG SUBSTANCE MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

12.6 EUROPE ANTI INFECTIVE DRUG SUBSTANCE MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

13.1 ASIA PACIFIC ANTI INFECTIVE DRUG SUBSTANCE MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

13.2 ASIA PACIFIC ANTI INFECTIVE DRUG SUBSTANCE MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

13.3 ASIA PACIFIC ANTI INFECTIVE DRUG SUBSTANCE MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

13.4 ASIA PACIFIC ANTI INFECTIVE DRUG SUBSTANCE MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

13.5 ASIA PACIFIC ANTI INFECTIVE DRUG SUBSTANCE MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

13.6 ASIA PACIFIC ANTI INFECTIVE DRUG SUBSTANCE MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

14.1 LATIN AMERICA ANTI INFECTIVE DRUG SUBSTANCE MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>

14.2 LATIN AMERICA ANTI INFECTIVE DRUG SUBSTANCE MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

14.3 LATIN AMERICA ANTI INFECTIVE DRUG SUBSTANCE MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

14.4 LATIN AMERICA ANTI INFECTIVE DRUG SUBSTANCE MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

14.5 LATIN AMERICA ANTI INFECTIVE DRUG SUBSTANCE MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

14.6 LATIN AMERICA ANTI INFECTIVE DRUG SUBSTANCE MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

15.1 MIDDLE EAST & AFRICA ANTI INFECTIVE DRUG SUBSTANCE MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

15.2 MIDDLE EAST & AFRICA ANTI INFECTIVE DRUG SUBSTANCE MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

15.3 MIDDLE EAST & AFRICA ANTI INFECTIVE DRUG SUBSTANCE MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

15.4 MIDDLE EAST & AFRICA ANTI INFECTIVE DRUG SUBSTANCE MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

15.5 MIDDLE EAST & AFRICA ANTI INFECTIVE DRUG SUBSTANCE MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

15.6 MIDDLE EAST & AFRICA ANTI INFECTIVE DRUG SUBSTANCE MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>

16.1 Qilu Pharmaceutial

  16.1.1 COMPANY DETAILS

  16.1.2 FINANCIALS (USD MILLION)

  16.1.3 PRODUCT SUMMARY

  16.1.4 RECENT DEVELOPMENTS

16.2 Kopran

16.3 Orchid Pharma

16.4 Nectar Lifesciences

16.5 Fresenius Kabi iPSUM

16.6 Sinopharm Weiqida Pharmaceutical

16.7 Dawnrays

16.8 Guangzhou Pi & Pi Biotech

16.9 CSPC Pharmaceutical

16.10 Hangzhou Viwa

16.11 Sterile India

16.12 Virchow Healthcare

16.13 Daewoong Bio

16.14 ACS Dobfar

16.15 United Laboratories International Holdings

18.1 METHODOLOGY

18.2 RESEARCH DATA SOURCE

  18.2.1 SECONDARY DATA

  18.2.2 KEY DATA FROM SECONDARY

  18.2.3 PRIMARY DATA

  18.2.4 KEY DATA FROM PRIMARY

  18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS

  18.2.6 MARKET ESTIMATION

  18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH

  18.2.8 LEGAL DISCLAIMER

Market Segments

Major Types Covered
Drug substance for skin infection
other
API for respiratory tract infection

Major Downstream Industry Covered
oral medicine
injection

Companies

Qilu Pharmaceutial
Kopran
Orchid Pharma
Nectar Lifesciences
Fresenius Kabi iPSUM
Sinopharm Weiqida Pharmaceutical
Dawnrays
Guangzhou Pi & Pi Biotech
CSPC Pharmaceutical
Hangzhou Viwa
Sterile India
Virchow Healthcare
Daewoong Bio
ACS Dobfar
United Laboratories International Holdings

Single User License  : 3900$
Corporate License    : 7800$
Enquiry Before Buying
Request For Customization
Speak To Analyst

BROWSE INDUSTRY

  1. Consumer Goods
  2. Healthcare
  3. Food & Beverage
  4. Heavy Industry
  5. Service Industries
  6. FMCG
  7. Life Sciences
  8. Technology & Media
  9. Machinery & Equipment

    WHY CHOOSE US

  •   PROACTIVE

    • We manage our resources 24/7 to identify issues and address them before they become problems.

  •   QUALITY & RELIABILITY

    • We are committed to providing reliable and highly accurate data with an excellent quality control system.

  •   GLOBAL OUTREACH

    • 6 Major regions and 40+ countries level analysis accomplished.

  •   COMPETITIVE PRICING

    • Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.